edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Cantargia
Edison Investment Research has terminated coverage on Cantargia (CANTA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme, the most advanced being a Phase IIa CANFOUR trial for pancreatic cancer and non-small cell lung cancer. CAN10 is being developed for systemic sclerosis and myocarditis, with clinical development expected to start in early 2022.
In this video, the company’s chief executive officer Göran Forsberg provides an update on R&D progress, including a summary of the promising results Cantargia recently reported from the pancreatic cancer arm of the CANFOUR trial.
Get access to the very latest content matched to your personal investment style.